FDA grants priority review to Pfizer TALZENNA-XTANDI combo in metastatic prostate cancer

Pfizer Inc.

Pfizer Inc.

PFE

0.00
  • FDA accepted Pfizer’s priority review for TALZENNA with XTANDI in HRR-altered metastatic castration-sensitive prostate cancer.
  • PDUFA action date set for Q4 2026; approval would expand use from metastatic castration-resistant disease.
  • TALAPRO-3 data showed a 52% reduction in risk of radiographic progression or death versus placebo with XTANDI.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607221630BIZWIRE_USPR_____20260722_BW156396) on July 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.